This Article Full Text Full Text (PDF) Other Versions of this Article: AAC.01063-07v1 52/3/1066    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by de Requena, D. G. Articles by Di Perri, G. Search for Related Content PubMed PubMed Citation Articles by de Requena, D. G. Articles by Di Perri, G.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 2008, p. 1066-1071, Vol. 52, No. 3
0066-4804/08/$08.00+0     doi:10.1128/AAC.01063-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Tipranavir (TPV) Genotypic Inhibitory Quotient Predicts Virological Response at 48 Weeks to TPV-Based Salvage Regimens

Department of Infectious Diseases, University of Turin, Turin, Italy,¹ Laboratory of Virology, Ospedale Amedeo di Savoia, Turin, Italy²

Received 12 August 2007/ Returned for modification 5 October 2007/ Accepted 14 December 2007

The virological response (VR) to a tipranavir-ritonavir (TPV-RTV)-based regimen had been shown to be associated with a number of mutations in the protease gene, the use of enfuvirtide (T20), and the TPV phenotypic inhibitory quotient (IQ). The role of the TPV genotypic IQ (gIQ) has not yet been fully investigated. The aim of our study was to evaluate the relationship between the TPV gIQ and the VR at 48 weeks to TPV-based salvage regimens. Patients placed on regimens containing two nucleoside reverse transcriptase inhibitors plus TPV-RTV 500/200 mg twice a day with or without T20 were prospectively studied. Regular follow-up was performed over the study period. VR, considered a viral load (VL) decrease of 1 log unit and/or the achievement of <50 copies/ml with no VL rebound of >0.5 log unit compared to the maximal VL decrease at week 48, was assessed. Thirty-eight patients who had received multiple drugs were included. At week 48 the VL decrease was –1.48 (interquartile range [IQR], –2.88 to –0.48), 15 patients (39.5%) had VLs of <50 copies/ml, and the CD4⁺ cell count increase was 37 cells/mm³ (IQR, –30 to +175). Twenty subjects (52.6%) achieved VRs. The TPV gIQ and optimized background score (OBS) were independently associated with higher VL decreases. The TPV gIQ and OBS were also independent predictors of a VR at week 48. TPV gIQ and OBS cutoff values of 14,500 and 2, respectively, were associated with a higher rate of VR. The TPV gIQ was shown to be able to predict the VR at 48 weeks to TPV-containing salvage regimens better than the TPV trough concentration or TPV-associated mutations alone. A possible TPV gIQ cutoff value of 14,500 for reaching a VR at week 48 was suggested. Further studies are needed in order to evaluate the calculation of TPV gIQ as a new tool for the optimization of TPV-based salvage therapy.

Published ahead of print on 26 December 2007.

This article has been cited by other articles:

• Molto, J., Santos, J. R., Perez-Alvarez, N., Cedeno, S., Miranda, C., Khoo, S., Else, L., Llibre, J. M., Valle, M., Clotet, B. (2008). Darunavir Inhibitory Quotient Predicts the 48-Week Virological Response to Darunavir-Based Salvage Therapy in Human Immunodeficiency Virus-Infected Protease Inhibitor-Experienced Patients. Antimicrob. Agents Chemother. 52: 3928-3932 [Abstract] [Full Text]